Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

In this study, 75% of alopecia areata patients showed improvement after treatment with 35% trichloroacetic acid, leading the researchers to conclude it is a safe and effective option for treating this condition.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This article reviews studies showing AT-Grow as effective in treating benign prostatic disease due to its anti-androgen properties but reports no new findings on its effect on hair growth.

This study observed that upadacitinib demonstrated significant efficacy and favorable safety for treating alopecia areata over 12 months in a real-world setting, with patients having an atopic background showing better early response; no serious adverse events were reported.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This study suggests that long-term treatment with the contact sensitizer SADBE in mice may reduce leucocyte traffic in alopecia areata through impaired leucocyte extravasation.

Teledermatology reduces unnecessary in-person visits and improves care.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that the active use of androgen deprivation therapy was not associated with a reduced risk of death in prostate cancer patients with COVID-19.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

CRT is more effective than oral minoxidil alone for treating hair loss.

THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

This study identified a key Arabidopsis thaliana gene, TIP1, whose product is involved in S-acylation crucial for normal plant cell growth, particularly affecting root hair development.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This study reported that dithranol treatment up to 3% concentration led to hair regrowth in alopecia areata patients who had previously failed ultra-potent steroids, with regrowth observed across all severity levels.

This study found that transcutaneous electrical acustimulation aided wound healing in mice by enhancing expression of proteins related to signaling pathways, stress recovery, and mitochondrial function.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.